Doxurubicin versus doxorubicin and cisplatin in endometrial carcinoma: Definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group

Annals of Oncology

Volumn 14, Issue 3, 2003, Pages 441-448

  Aapro, M S ^a   van Wijk, F H ^b   Bolis, G ^c   Chevallier, B ^d   van der Burg, M E L ^e   Poveda, A ^f   de Oliveira, C F ^g   Tumolo, S ^h   Scotto di Palumbo, V ⁱ   Piccart, M ^j   Franchi, M ^k   Zanaboni, F ^l   Lacave, A J ^m   Fontanelli, R ^l   Favalli, G ⁿ   Zola, P ^o   Guastalla, J P ^p   Rosso, R ^q   Marth, C ^r   Nooij, M ^s   Presti, M ^t   Scarabelli, C ^t   Splinter, T A W ^e   Ploch, E ^u   Beex, L V A ^v   ten Bokkel Huinink, W ^w   Forni, M ^a   Melpignano, M ^x   Blake, P ^y   Kerbrat, P ^z   Mendiola, C ^aa   Cervantes, A ^ab   Goupil, A ^ac   Harper, P G ^ad   Madronal, C ^ae   Namer, M ^af   Scarfone, G ^b   Stoot, J E G M ^ag   Teodorovic, I ^a   Coens, C ^a   Vergote, I ^ah   Vermorken, J B ^ai   more..

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b EORTC DATA CENTER   (Belgium)

^c Istituto L Mangiagalli   (Italy)

^d CENTRE HENRI BECQUEREL   (France)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^g CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^h Azienda Ospedaliera SMDAngeli   (Italy)

ⁱ Osp Gen Province San C de Lellis   (Italy)

^j JULES BORDET INSTITUTE   (Belgium)

^k Ospedale Circolo Fondazione Macchi   (Spain)

^l NATIONAL CANCER INSTITUTE   (Italy)

^m HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

ⁿ UNIVERSITY OF BRESCIA   (Italy)

^o MAURIZIANO HOSPITAL   (Italy)

^p CENTRE LÉON BÉRARD   (France)

^q UNIVERSITY OF GENOA   (Italy)

^r UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^s LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^t Ospedale Civile   (Italy)

^u INSTITUTE OF ONCOLOGY   (Poland)

^v RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^w ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^x UNIVERSITY HOSPITAL OF PARMA   (Italy)

^y ROYAL MARSDEN HOSPITAL   (United Kingdom)

^z CENTRE EUGÈNE MARQUIS   (France)

^aa HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^ab HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^ac CENTRE RENÉ HUGUENIN   (France)

^ad GUY S HOSPITAL   (United Kingdom)

^ae Institut Catalan d'Oncologia   (Spain)

^af Centre Antoine Lassagne   (France)

^ag Sittard Geleen Heerlen   (Netherlands)

^ah University of Hospital   (Belgium)

^ai VU UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

Chemotherapy; Cisplatin; Doxorubin; Endometrial carcinoma; Phase III; Randomised clinical trial

Indexed keywords

ANTIEMETIC AGENT; CISPLATIN; DOXORUBICIN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC;

ADULT; ADVANCED CANCER; AGED; ALLERGY; ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE PAIN; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG FEVER; DRUG RESPONSE; ENDOMETRIUM CANCER; FOLLOW UP; GASTROINTESTINAL TOXICITY; HEARING LOSS; HEART DISEASE; HEMATOLOGIC DISEASE; HISTOPATHOLOGY; HUMAN; INFECTION; LUNG DISEASE; MAJOR CLINICAL STUDY; MONOTHERAPY; MOUTH DISEASE; MUSCLE WEAKNESS; NAUSEA; NEUROTOXICITY; PARESTHESIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; SKIN DISEASE; STATISTICAL SIGNIFICANCE; VOMITING; ADENOCARCINOMA; ENDOMETRIUM TUMOR; FEMALE; HEALTH STATUS; INTRAVENOUS DRUG ADMINISTRATION; MALE; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PROGNOSIS; SURVIVAL; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DOXORUBICIN; ENDOMETRIAL NEOPLASMS; FEMALE; HEALTH STATUS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0037352608     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdg112     Document Type: Article

References (24)

1. Glassburn JR. Carcinoma of the endometrium. Cancer 1981; 48 (Suppl 2): 575-581.
2. Kelly RM, Baker WH. Progestational agents in the treatment of carcinoma of the endometrium. N Engl J Med 1961; 264: 216.
3. Donovan JF. Nonhormonal chemotherapy of endometrial adenocarcinoma: a review. Cancer 1974; 34: 1587-1592.
4. Carbone PP, Carter SK. Endometrial cancer: approach to development of effective chemotherapy. Gynecol Oncol 1974; 2: 348-353.
5. Deppe G. Chemotherapeutic treatment of endometrial carcinoma. Clin Obstet Gynecol 1982; 25: 93-99.
6. Cohen CJ. Cytotoxic chemotherapy for patients with endometrial carcinoma. Clin Obstet Gynaecol 1986; 13: 811-824.
7. Bruckner HW, Cohen CJ, Goldberg JD et al. Improved chemotherapy for ovarian cancer with cis-diamminedichloroplatinum and adriamycin. Cancer 1981; 49: 2441-2445.
8. George SL, Desu MM. Planning the size and duration of a clinical trial studying the time to some critical event. J Chron Dis 1974; 27: 15-24.
9. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975; 31: 103-115.
10. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
11. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163-170.
12. Cox DR. Regression models and life-tables. J R Stat Soc B 1972; 34: 187-202.
13. Thigpen JT, Blessing JA, Ball H et al. Hexamethylmelamine as first-line chemotherapy in the treatment of advanced or recurrent carcinoma of the endometrium: a phase II trial of the Gynecologic Oncology Group. Gynecol Oncol 1988; 31: 435-438.
14. Burke TW, Munkarah A, Kavanagh JJ et al. Treatment of advanced or recurrent endometrial carcinoma with single-agent carboplatin. Gynecol Oncol 1993; 51: 397-400.
15. Thigpen JT, Blessing JA, Homesley H et al. Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 1989; 33: 68-70.
16. Martin M. Platinum compounds in the treatment of advanced breast cancer. Clin Breast Cancer 2001; 3: 190-208.
17. Deppe G, Malviya VK, Malone JM et al. Treatment of recurrent and metastatic endometrial carcinoma with cisplatin and doxorubicin. Eur J Gynaecol Oncol 1984; 15: 263-266.
18. Seltzer V, Vogl SE, Kaplan BH. Adriamycin and cis-diamminedichloro-platinum in the treatment of metastatic endometrial adenocarcinoma. Gynecol Oncol 1984; 19: 308-313.
19. Tropé C, Johnson JE, Simonsen E et al. Treatment of recurrent endometrial carcinoma with a combination of doxorubicin and cisplatin. Am J Obstet Gynecol 1984; 149: 379-381.
20. Pasmantier MW, Coleman M, Silver RT et al. Treatment of advanced endometrial carcinoma with doxorubicin and cisplatin: effect on both untreated and previously treated patients. Cancer Treat Rep 1985; 69: 539-542.
21. Barrett RJ, Blessing JA, Homesley H et al. Circadian-timed combination doxorubicin-cisplatin chemotherapy for advanced endometrial carcinoma: a phase II study of the Gynecologic Oncology Group. Am J Clin Oncol 1993; 16: 494-496.
22. Thigpen TJ, Blessing JA, Homesley H et al. Phase III trial of doxorubicin ± cisplatin in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group (GOG) study. Proc Am Soc Clin Oncol 1993; 12: 261 (Abstr).
23. Long HJ, Nelimark RA, Cha SS. Comparison of methotrexate, vinblastine, doxorubicin and cisplatin (MVAC) versus doxorubicin and cisplatin (AC) in advanced endometrial carcinoma. Proc Am Soc Clin Oncol 1991: 14: 282 (Abstr).
24. Aapro M, Bolis G, Chevallier B et al. Doxorubicin versus doxorubicin plus cisplatin in endometrial carcinoma: a randomized study of the EORTC Gynecological Cancer Cooperative Group (GCCG) (Meeting abstract). Ann Oncol 1994; 5 (Suppl 8): 98.